People who developed sudden vision loss or were diagnosed with non-arteritic anterior ischemic optic neuropathy, often called NAION, after using Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs may have legal options. Patients across the United States have begun filing lawsuits alleging that these medications caused serious optic nerve injuries that can lead to permanent vision impairment or blindness. 

In December 2025, the federal judiciary took a major step in the growing litigation involving GLP-1 medications and vision injuries. A panel of federal judges ordered that lawsuits alleging blindness or NAION caused by GLP-1 receptor agonist drugs be consolidated into one federal multidistrict litigation. Centralizing these cases allows courts to address common scientific questions about whether drugs such as Ozempic and Wegovy may contribute to optic nerve damage and permanent vision loss. 

If you or a family member experienced sudden vision loss after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, you may qualify to file a lawsuit and receive compensation.  

The law firm of Hissey Mulderig & Friend is investigating claims involving NAION and other serious vision injuries linked to GLP-1 drugs. For a free legal consultation or to start your claim today, please call our office toll-free at 1-866-806-8117, or complete our free case evaluation form, located on the right side of this page. 

What the GLP-1 Vision Loss MDL Means

Multidistrict litigation is commonly used when large numbers of lawsuits involve similar allegations and scientific evidence. Instead of handling each case separately in courts around the country, related claims are transferred to one federal judge for coordinated pretrial proceedings. 

At the time the litigation was centralized, dozens of lawsuits had already been filed alleging that GLP-1 medications contributed to severe vision problems. Attorneys expect the number of claims to increase as more patients learn about the potential connection between these drugs and optic nerve injuries. 

The federal judicial panel overseeing the consolidation determined that the vision loss lawsuits involve medical and scientific questions that are distinct from other GLP-1 drug claims. For example, some lawsuits involving these medications focus on gastrointestinal complications such as gastroparesis. Because the alleged vision injuries involve different biological mechanisms and medical evidence, the NAION cases were placed into their own multidistrict litigation. 

As the litigation moves forward, the court will oversee discovery, expert testimony, and other pretrial proceedings related to the alleged link between GLP-1 medications and optic nerve damage. 

GLP-1 Drugs Named in Vision Loss Lawsuits

GLP-1 receptor agonists are medications commonly prescribed to treat type 2 diabetes and, more recently, obesity. These drugs mimic a hormone that helps regulate blood sugar levels and appetite. 

Several widely used medications fall into this category, including: 

• Ozempic 
• Wegovy 
• Mounjaro 
• Rybelsus 
• Saxenda 
• Trulicity 

Because of their effectiveness in lowering blood sugar and promoting weight loss, GLP-1 drugs have become extremely popular. Millions of people in the United States have taken these medications over the past several years. 

However, as the use of these drugs has expanded, researchers and regulators have begun examining potential safety concerns. Among the most serious issues being investigated is whether GLP-1 medications may increase the risk of optic nerve injuries that can lead to permanent vision loss. 

Understanding NAION and Sudden Vision Loss

Non-arteritic anterior ischemic optic neuropathy is a condition that occurs when blood flow to the optic nerve becomes insufficient. The optic nerve is responsible for transmitting visual signals from the eye to the brain. 

When the nerve does not receive enough blood supply, permanent damage can occur. NAION often develops suddenly and without warning. 

Patients diagnosed with NAION may experience symptoms such as: 

• Sudden vision loss in one eye 
• Blurred or dim vision 
• Missing or dark areas in the field of vision 
• Vision changes that appear suddenly upon waking 

For many individuals, the vision loss caused by NAION cannot be reversed. Because the optic nerve is damaged, the condition can result in lasting impairment or blindness. 

Why Patients Are Filing Ozempic Vision Loss Lawsuits

People who developed NAION after taking Ozempic or another GLP-1 medication have filed lawsuits alleging that these medications may increase their risk of developing NAION, and that drug manufacturers failed to adequately warn patients and physicians about the risk of optic nerve injuries. 

Many of these lawsuits claim that individuals were not informed that GLP-1 drugs might increase the likelihood of serious vision problems. Without this information, patients may not have been able to fully evaluate the potential risks before starting treatment. 

The lawsuits generally raise allegations such as: 

• Failure to warn about the risk of NAION or optic nerve damage 
• Inadequate safety testing related to vision complications 
• Misrepresentation of the drugs’ safety profile 

Drug manufacturers deny these allegations, and the litigation will ultimately determine how courts evaluate the scientific evidence surrounding these claims. 

Research Examining the Possible Link Between GLP-1 Drugs and NAION

Interest in the potential connection between GLP-1 medications and optic nerve injuries increased after medical researchers began studying whether these drugs might affect blood flow to the eye. 

Some research has suggested that patients using semaglutide or related medications may face a higher risk of developing NAION compared with individuals taking other diabetes treatments. Researchers continue to investigate the issue to determine whether the medications themselves contribute to the condition or whether other factors may be involved. 

Scientists are examining several possible explanations, including: 

• Changes in blood circulation affecting the optic nerve 
• Effects on blood pressure or vascular health 
• Interactions with existing risk factors such as diabetes or cardiovascular disease 

Additional research will likely play an important role as courts evaluate the scientific evidence in the GLP-1 vision loss litigation. 

Who May Qualify to File an Ozempic Vision Loss Lawsuit

Individuals who took Ozempic, Wegovy, Mounjaro, or another GLP-1 receptor agonist and later developed serious vision problems may be exploring whether they qualify to file a lawsuit. 

Many of the cases filed so far involve patients who: 

• Used a GLP-1 medication for diabetes or weight loss 
• Experienced sudden vision loss or severe visual symptoms 
• Were later diagnosed with NAION or another optic nerve injury 

Determining whether a legal claim may be available often depends on several factors, including a patient’s medical history, the timing of symptoms, and the diagnosis provided by physicians. 

Contact An Attorney to Understand Your Legal Options After GLP-1 Vision Loss

The creation of the federal NAION multidistrict litigation represents an early stage in what could become significant pharmaceutical litigation involving GLP-1 drugs. 

Patients who developed NAION, blindness, or sudden vision loss after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication may have the right to pursue compensation through the ongoing litigation. 

Our law firm, Hissey Mulderig & Friend, has a team of lawyers with more than 100 years of combined legal experience. Our firm works on a strict contingency, meaning you will never pay legal fees unless we successfully recover damages in your case.

If you or a loved one experienced vision loss after using Ozempic or another GLP-1 drug, contact the law firm of Hissey Mulderig & Friend to learn whether you qualify or to start your claim today. You can reach us by calling our office toll-free at 1-866-806-8117, or by filling out our free claim submission form, located at the top of this page.